Koga S, Nishikido M, Matsuya F, Kanetake H, Saito Y
Department of Urology, Nagasaki University School of Medicine, Japan.
Anticancer Res. 1999 Nov-Dec;19(6C):5547-50.
Renal cell carcinoma (RCC) is relatively resistant to both chemotherapy and radiotherapy. Response and survival of treatment with Interferon-alpha (IFN-alpha) and Interferon-gamma (IFN-gamma) were evaluated in patients with metastatic RCC.
Thirty-one patients with confirmed RCC were included in this study. Fifteen of 31 patients received injection of IFN-alpha and IFN-gamma three times a week. IFN-gamma was infused subcutaneously by microinfusion pump. Sixteen received IFN-alpha alone more than three times a week.
The overall response rate was 20.0% in the IFN-alpha and IFN-gamma group, and 12.5% in the IFN-alpha alone group. Long lasting stabilization of the disease (more than; 12 months) was seen in 92.3% of CR, PR or SD in the IFN-alpha and IFN-gamma group, as compared with 71.4% in the IFN-alpha alone group. Both groups differed significantly in survival rate from the first treatment with IFN (p < 0.05).
A long lasting stabilization of the disease can be expected in patients who were treated with our regimen of IFN-alpha and IFN-gamma.
肾细胞癌（RCC）对化疗和放疗均相对耐药。对转移性肾细胞癌患者使用α干扰素（IFN-α）和γ干扰素（IFN-γ）治疗的反应及生存情况进行了评估。
本研究纳入31例确诊为肾细胞癌的患者。31例患者中有15例每周接受3次IFN-α和IFN-γ注射。IFN-γ通过微量输注泵皮下输注。16例患者每周接受3次以上的单独IFN-α注射。
IFN-α和IFN-γ联合组的总体缓解率为20.0%，单独使用IFN-α组为12.5%。IFN-α和IFN-γ联合组中92.3%达到完全缓解（CR）、部分缓解（PR）或疾病稳定（SD）的患者疾病获得长期稳定（超过12个月），而单独使用IFN-α组为71.4%。两组从首次使用IFN治疗起的生存率差异有统计学意义（p<0.05）。
采用我们的IFN-α和IFN-γ治疗方案的患者有望实现疾病的长期稳定。
